- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine

The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine
Latest news
Latest newsUzbekistan Bets on Georgian Ports as Tashkent Expands Its Trade Route to European Markets via the Black Sea
14.Jul.2026
Turkmenistan and the USA Explore New Areas of Cooperation as Ashgabat Hosts U.S. Senator Steve Daines
13.Jul.2026
Engineers Instead of Soldiers: Kazakhstan Hosts Its First Engineering Technologies Championship
12.Jul.2026
Transit Instead of Confrontation: Russia Expands Cargo Shipments to Armenia via Azerbaijan
12.Jul.2026
Europe Accelerates Rearmament: EU Countries Prioritize Missiles, Air Defense Systems, and Drones
10.Jul.2026
Russia Begins Using New FPV Drones to Strike Ukraine's Energy Infrastructure
10.Jul.2026
US Ready to Lift Sanctions on Turkiye and Restore Its Participation in the F-35 Program
09.Jul.2026
Trump Announces Transfer of License to Ukraine for Patriot Interceptor Missile Production
09.Jul.2026
The NATO Summit in Ankara Marked a New Stage in the Alliance's Transformation
08.Jul.2026
The war in Ukraine - the “liberation of Novorossiya” is a mission impossible
07.Jul.2026

18 Jul 2026


